Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger protein 260 pseudogene (ENSG00000255057) is annotated in Ensembl as a pseudogene, meaning it is a genomic DNA sequence similar to but nonfunctional relative to a protein-coding gene—in this case, similar to the active ZNF260 ("Zinc finger protein 260"). Pseudogenes generally do not encode functional proteins due to mutations or deletions; as such, this entity is not a therapeutic target, is not a receptor, enzyme, or transcription factor, and is absent from curated drug, biomarker, or disease association databases. The active form of zinc finger protein 260 (ZNF260) functions as a transcription factor and cardiac regulator[1][5], but the pseudogene itself has no established function, clinical role, or druggability[1][5]. Notes on correctness: This target is flagged as "incorrect" for drug targeting purposes because it is a pseudogene, not an active molecular target. Pseudogenes are not considered functional drug targets and usually lack protein expression, interaction, or disease roles relevant for therapeutic intervention.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Zinc finger protein 260 pseudogene.